Stock Market

Sorrento Has Potential To Deliver Multiple Best-In-Class Products

  • Cantor Fitzgerald initiated coverage on Sorrento Therapeutics Inc (NASDAQ: SRNE) with an Overweight rating and a price target of $5.

  • The analyst says Sorrento has the potential to deliver multiple best-in-class products in high-value areas of oncology, pain, and infectious disease, highlighting three value drivers:

    • Scilex’s potential in non-opioid pain. Its pain portfolio currently has marketed and pipeline programs, which could unlock further meaningful value.

    • Abivertinib’s potential in non-small cell lung cancer

    • A conservative platform value is believed to allow investors to be rewarded from current levels over the near term and over the longer term as other pipeline programs come to the fore.

  • In August, abivertinib showed significant treatment benefits in 209 response-evaluable, heavily pretreated NSCLC patients, with an ORR of 56.5%.

  • A significant CR rate was seen with Abivertinib (5.3%) compared to AstraZeneca Plc’s (NASDAQ: AZN) Tagrisso (osimertinib) (0.5%), overall survival of 28.2 months (versus Tagrisso’s median OS of 26.8 months).

  • Price Action: SRNE shares are down 0.95% at $1.57 on the last check Wednesday.

Latest Ratings for SRNE






Aug 2021

HC Wainwright & Co.



Jan 2021

Alliance Global Partners

Initiates Coverage On


Jul 2020

HC Wainwright & Co.



View More Analyst Ratings for SRNE

View the Latest Analyst Ratings

See more from Benzinga

Don’t miss real-time alerts on your stocks – join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga does not provide investment advice. All rights reserved.


Share this news on your Fb,Twitter and Whatsapp

File source

NY Press News:Latest News Headlines
NY Press News||Health||New York||USA News||Technology||World News

Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button